How can we prevent diarrhea induced by systemic treatments in oncological patients? An evaluation of phase II trials

References

• Rutledge DN, Engelking E. Cancer treatment-related diarrhea: challenges and barriers to clinical practice. Oncology Nursing Updates. 1998;5:1–16. PMID: 9644702 .
   Google Scholar
• Stein A, Voigt W, Jordan K. Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. Ther Adv Medi Oncol. 2010;2(1):51–63. doi: 10.1177/1758834009355164
   PubMedGoogle Scholar
• Sweetser S. Evaluating the patient with diarrhea: a case-based approach. Mayo Clin Proc. 2012 Jun;87(6):596–60. doi: 10.1016/j.mayocp.2012.02.015
   PubMed Web of Science ®Google Scholar
• Bossi P, Antonuzzo A, Cherny NI, et al. ESMO guidelines committee. Diarrhoea in adult cancer patients: ESMO clinical practice guidelines. Ann Oncol. 2018 Oct 1;29(Suppl 4):iv126–iv142. doi: 10.1093/annonc/mdy145
   PubMedGoogle Scholar
• Michael M, Brittain M, Nagai J, et al. Phase II study of activated charcoal to prevent irinotecan-induced diarrhea. J Clin Oncol. 2004;22(21):4410–4417. doi: 10.1200/JCO.2004.11.125
   PubMed Web of Science ®Google Scholar
• Tobin PJ, Beale P, Noney L, et al. A pilot study on the safety of combining chrysin, a non-absorbable inducer of UGT1A1, and irinotecan (CPT-11) to treat metastatic colorectal cancer. Cancer Chemother Pharmacol. 2006;57(3):309–316. doi: 10.1007/s00280-005-0053-0
   PubMed Web of Science ®Google Scholar
• Ychou M, Doulliard JY, Rougier P, et al. Randomized comparison of prophylactic antidiarrheal treatment versus no prophylactic antidiarrheal treatment in patients receiving CPT-11 (irinotecan) for advanced 5FU-resistant colorectal cancer: an open label multicentre phase II study. Am J Clin Oncol. 2000;23(2):143–148. doi: 10.1097/00000421-200004000-00008
   PubMed Web of Science ®Google Scholar
• Govindarajan R, Heaton KM, Broadwater JR, et al. Effect of thalidomide on gastrointestinal toxic effects of irinotecan. Lancet (London, England). 2000;356(9229):566–567. doi: 10.1016/S0140-6736(00)02586-1
   PubMed Web of Science ®Google Scholar
• Delioukina ML, Prager D, Parson M, et al. Phase II trial of irinotecan in combination with amifostine in patients with advanced colorectal carcinoma. Cancer. 2002 Apr;94(8):2174–2179. doi: 10.1002/cncr.10432
   PubMed Web of Science ®Google Scholar
• Mori K, Kondo T, Kamiyama Y, et al. Preventive effect of Kampo medicine (hangeshashin-to) against irinotecan-induced diarrhea in advanced non-small-cell lung cancer. Cancer Chemother Pharmacol. 2003;51(5):403–406. doi: 10.1007/s00280-003-0585-0
   PubMed Web of Science ®Google Scholar
• Kee BK, Morris JS, Slack RS, et al. A phase II, randomized, double blind trial of calcium aluminosilicate clay versus placebo for the prevention of diarrhea in patients with metastatic colorectal cancer treated with irinotecan. Support Care Cancer. 2014 Aug 27;23(3):661. Epub. doi: 10.1007/s00520-014-2402-1
   PubMed Web of Science ®Google Scholar
• A Phase II Multicenter, Randomized, Placebo Controlled, Double blinded clinical study of KD018 as a modulator of irinotecan chemotherapy in patients with metastatic colorectal cancer. ClinicalTrials.gov Identifier: NCT00730158
   Google Scholar
• Namikawa T, Munekage E, Maeda H, et al. Feasibility study of supportive care using lafutidine, a histamine H2 receptor antagonist, to prevent gastrointestinal toxicity during chemotherapy for gastric cancer. Anticancer Res. 2014 Dec;34(12):7297–7301. PMID: 25503163 .
   PubMed Web of Science ®Google Scholar
• Rotovnik Kozjek N, Kompan L, Soeters P, et al. Oral glutamine supplementation during preoperative radiochemotherapy in patients with rectal cancer: a randomised double blinded, placebo controlled pilot study. Clin Nutr. 2011 Oct;30(5):567–570. doi: 10.1016/j.clnu.2011.06.003
   PubMed Web of Science ®Google Scholar
• Decker-Baumann C, Buhl K, Frohmüller S, et al. Reduction of chemotherapy-induced side-effects by parenteral glutamine supplementation in patients with metastatic colorectal cancer. Eur J Cancer. 1999;35(2):202–207. Feb. doi: 10.1016/S0959-8049(98)00389-X
   PubMed Web of Science ®Google Scholar
• Bozzetti F, Biganzoli L, Gavazzi C, et al. Glutamine supplementation in cancer patients receiving chemotherapy: a double-blind randomized study. Nutrition. 1997 Jul;13(7–8):748–751. doi: 10.1016/S0899-9007(97)83038-9
   PubMed Web of Science ®Google Scholar
• Daniele B, Perrone F, Gallo C, et al. Oral glutamine in the prevention of fluorouracil induced intestinal toxicity: a double blind, placebo controlled, randomised trial. Gut. 2001 Jan;48(1):28–33. doi: 10.1136/gut.48.1.28
   PubMed Web of Science ®Google Scholar
• Bradstock KF, Link E, Collins M, et al. Australasian leukaemia and lymphoma group, a randomized trial of prophylactic palifermin on gastrointestinal toxicity after intensive induction therapy for acute myeloid leukaemia. Br J Haematol. 2014;167(5):618–625. doi: 10.1111/bjh.13086
   PubMed Web of Science ®Google Scholar
• Herbers AH, van der Velden WJ, de Haan AFJ, et al. Impact of palifermin on intestinal mucositis of HSCT recipients after BEAM. Bone Marrow Transplant. 2014;49(1):8–10. doi: 10.1038/bmt.2013.118
   PubMed Web of Science ®Google Scholar
• Bowen JM, Gibson RJ, Coller JK, et al. Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO). Systematic review of agents for the management of cancer treatment-related gastrointestinal mucositis and clinical practice guidelines. Support Care Cancer. 2019 Oct;27(10):4011–4022. doi: 10.1007/s00520-019-04892-0
   PubMedGoogle Scholar
• Nobre LMS, Fernandes C, Florêncio KG, et al. Could paraprobiotics be a safer alternative to probiotics for managing cancer chemotherapy-induced gastrointestinal toxicities? Braz J Med Biol Res. 2023 Jan 16;55:e12522. doi: 10.1590/1414-431X2022e12522
   PubMed Web of Science ®Google Scholar
• Mego M, Chovanec J, Vochyanova-Andrezalova I, et al. Prevention of irinotecan induced diarrhea by probiotics: a randomized double blind, placebo controlled pilot study. Complement Ther Med. 2015;23(3):356–362. doi: 10.1016/j.ctim.2015.03.008
   PubMed Web of Science ®Google Scholar
• Osterlund P, Ruotsalainen T, Korpela R, et al. Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study. Br J Cancer. 2007;97(8):1028–1034. doi: 10.1038/sj.bjc.6603990
   PubMed Web of Science ®Google Scholar
• Zaharuddin L, Mokhtar NM, Muhammad Nawawi KN, et al. A randomized double-blind placebo-controlled trial of probiotics in post-surgical colorectal cancer. BMC Gastroenterol. 2019;19(1):131. doi: 10.1186/s12876-019-1047-4
   PubMed Web of Science ®Google Scholar
• Doron S, Snydman DR. Risk and safety of probiotics. Clin Infect Dis. An official publication of the Infectious Diseases Society of America. 2015;60(Suppl 2):S129–S134. doi: 10.1093/cid/civ085.
   PubMed Web of Science ®Google Scholar
• Suez J, Zmora N, Segal E, et al. The pros, cons, and many unknowns of probiotics. Nat Med. 2019 May;25(5):716–729. doi: 10.1038/s41591-019-0439-x
   PubMed Web of Science ®Google Scholar
• Ianiro G, Rossi E, Thomas AM, et al. Faecal microbiota transplantation for the treatment of diarrhoea induced by tyrosine-kinase inhibitors in patients with metastatic renal cell carcinoma. Nat Commun. 2020 Aug;11(1):4333. doi: 10.1038/s41467-020-18127-y
   PubMed Web of Science ®Google Scholar
• Fecal microbiota transplantation in treating immune-checkpoint inhibitor induced-diarrhea or colitis in genitourinary cancer patients. ClinicalTrials Gov Identifier. NCT04038619
   Google Scholar
• Fischer H, Machen TE, Widdicombe JH, et al. A novel extract SB-300 from the stem bark latex of Croton lechleri inhibits CFTR-mediated chloride secretion in human colonic epithelial cells. J Ethnopharmacol. 2004;93(2–3):351–357. doi: 10.1016/j.jep.2004.04.005
   PubMed Web of Science ®Google Scholar
• Tradtrantip L, Namkung W, Verkman AS, et al. Crofelemer, an antisecretory antidiarrheal proanthocyanidin oligomer extracted from Croton lechleri, targets two distinct intestinal chloride channels. Mol Pharmacol. 2010;77(1):69–78. doi: 10.1124/mol.109.061051
   PubMed Web of Science ®Google Scholar
• Gao JJ, Tan M, Pohlmann PR, et al. HALT-D: a phase II evaluation of crofelemer for the prevention and prophylaxis of diarrhea in patients with breast cancer on pertuzumab-based regimens. Clin Breast Cancer. 2017;17(1):76–78. doi: 10.1016/j.clbc.2016.08.005
   PubMed Web of Science ®Google Scholar
• Pohlmann PR, Graham D, Wu T, et al. HALT-D: a randomized open-label phase II study of crofelemer for the prevention of chemotherapy-induced diarrhea in patients with HER2-positive breast cancer receiving trastuzumab, pertuzumab, and a taxane. Breast Cancer Res Treat. 2022 Dec;196(3):571–581. doi: 10.1007/s10549-022-06743-9
   PubMed Web of Science ®Google Scholar
• Prophylaxis of diarrhea in adult cancer patients receiving targeted cancer therapy (OnTARGET). ClinicalTrials.gov Identifier: NCT04538625
   Google Scholar
• Chan A, Ruiz-Borrego M, Marx G, et al. Final findings from the CONTROL trial: strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer. Breast Feb. 2023;67:94–101. doi: 10.1016/j.breast.2022.12.003
   PubMed Web of Science ®Google Scholar
• Trial to evaluate diarrhoea discontinuations at 3 cycles in patients with early-stage HER2+, HR+ breast cancer treated with neratinib plus loperamide versus neratinib dose escalation plus loperamide administered as needed versus neratinib plus loperamide plus colesevelam (DIANER). ClinicalTrials.gov Identifier: NCT05252988
   Google Scholar
• Prevention and treatment of pyrrolitinib-associated diarrhea. ClinicalTrials.gov Identifier: NCT04736186
   Google Scholar
• Clinical study on prevention and treatment of pyrotinib associated diarrhea with traditional Chinese medicine. ClinicalTrials.gov Identifier: NCT04988165
   Google Scholar
• Feasibility and safety of acupuncture in the prevention of late irinotecan-related diarrhea in pediatric patients. ClinicalTrials.gov Identifier: NCT05507736.
   Google Scholar